Severe hypocalcemia after denosumab administration in a patient with chronic kidney disease: a case report.

Autor:	Kouroglou E; Endocrinology and Metabolism Department, Hippocration Hospital, Athens, Greece., Tsiama V; Endocrinology and Metabolism Department, Hippocration Hospital, Athens, Greece., Dionysopoulou S; Endocrinology and Metabolism Department, Hippocration Hospital, Athens, Greece., Gavriiloglou G; Endocrinology and Metabolism Department, Hippocration Hospital, Athens, Greece., Bora M; Nephrology Department, Hippocration Hospital, Athens, Greece., Belis K; Endocrinology and Metabolism Department, Hippocration Hospital, Athens, Greece., Proikaki S; Endocrinology and Metabolism Department, Hippocration Hospital, Athens, Greece., Savvidis C; Endocrinology and Metabolism Department, Hippocration Hospital, Athens, Greece., Giannou P; Nephrology Department, Hippocration Hospital, Athens, Greece., Petras D; Nephrology Department, Hippocration Hospital, Athens, Greece.
Jazyk:	angličtina
Zdroj:	Journal of musculoskeletal & neuronal interactions [J Musculoskelet Neuronal Interact] 2023 Jun 01; Vol. 23 (2), pp. 285-289.
Abstrakt:	Patients with altered kidney function are at increased risk of hypocalcemia after denosumab administration. There is however a small number of studies and case reports describing hypocalcemia refractory to treatment. We describe a case of severe hypocalcemia, after the administration of three doses of denosumab, in a young patient with lupus nephritis under corticosteroid coverage and osteopenia. However, more studies are needed in order to extract a safe conclusion about the factors that contribute to the development of severe hypocalcemia in this group of patients. Competing Interests: The authors have no conflict of interest.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu